Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression.
BDNF
cytochromes
low-dose ketamine
rapid-acting antidepressants
sexual dimorphism
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
12 01 2022
12 01 2022
Historique:
received:
28
05
2021
revised:
08
10
2021
accepted:
15
11
2021
pubmed:
12
12
2021
medline:
17
3
2022
entrez:
11
12
2021
Statut:
ppublish
Résumé
Major depressive disorder (MDD) is a common psychiatric illness that manifests in sex-influenced ways. Men and women may experience depression differently and also respond to various antidepressant treatments in sex-influenced ways. Ketamine, which is now being used as a rapid-acting antidepressant, is likely the same. To date, the majority of studies investigating treatment outcomes in MDD do not disaggregate the findings in males and females, and this is also true for ketamine. This review aims to highlight that gap by exploring pre-clinical data-at a behavioral, molecular, and structural level-and recent clinical trials. Sex hormones, particularly estrogen and progesterone, influence the response at all levels examined, and sex is therefore a critical factor to examine when looking at ketamine response. Taken together, the data show females are more sensitive to ketamine than males, and it might be possible to monitor the phase of the menstrual cycle to mitigate some risks associated with the use of ketamine for females with MDD. Based on the studies reviewed in this article, we suggest that ketamine should be administered adhering to sex-specific considerations.
Identifiants
pubmed: 34894233
pii: 6432121
doi: 10.1093/ijnp/pyab082
pmc: PMC8756094
doi:
Substances chimiques
Antidepressive Agents
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-84Subventions
Organisme : Canadian Institute of Health Research
ID : FDN148374
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of CINP.
Références
Am J Psychiatry. 2016 Aug 1;173(8):816-26
pubmed: 27056608
J Neurosci Res. 2007 Aug 15;85(11):2441-9
pubmed: 17549730
CNS Neurosci Ther. 2013 Jun;19(6):370-80
pubmed: 23575437
Biol Psychiatry. 2012 Oct 1;72(7):555-61
pubmed: 22521148
Aust N Z J Psychiatry. 2017 Jan;51(1):55-64
pubmed: 26893373
Int J Neuropsychopharmacol. 2014 Aug;17(8):1321-6
pubmed: 24852262
Int Rev Psychiatry. 2010;22(5):485-500
pubmed: 21047161
J Affect Disord. 2003 Mar;74(1):5-13
pubmed: 12646294
Arch Gen Psychiatry. 2008 Feb;65(2):154-64
pubmed: 18250253
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E3007-E3016
pubmed: 29531088
Biol Psychiatry. 2013 Jun 15;73(12):1199-203
pubmed: 23062356
J Neurophysiol. 1987 Aug;58(2):251-66
pubmed: 2443623
Int Clin Psychopharmacol. 2008 Jul;23(4):188-97
pubmed: 18545056
Biol Psychiatry. 2008 Feb 15;63(4):349-52
pubmed: 17643398
World J Biol Psychiatry. 2010 Sep;11(6):763-73
pubmed: 20334574
J Womens Health (Larchmt). 2010 Sep;19(9):1727-32
pubmed: 20799923
Neuropharmacology. 2018 Mar 1;130:30-41
pubmed: 29175352
Curr Opin Pharmacol. 2007 Feb;7(1):18-21
pubmed: 17049922
J Psychiatr Res. 2019 Mar;110:166-171
pubmed: 30641350
Cell. 2006 Sep 8;126(5):955-68
pubmed: 16959574
Neuroscience. 2012 Jun 28;213:72-80
pubmed: 22521815
Eur Psychiatry. 2014 Sep;29(7):419-23
pubmed: 24321772
Int J Neuropsychopharmacol. 2017 Nov 1;20(11):909-918
pubmed: 29099972
Psychopharmacology (Berl). 2017 Feb;234(3):393-401
pubmed: 27837330
World J Biol Psychiatry. 2020 Nov;21(9):696-710
pubmed: 31680600
Nature. 2017 Jun 21;546(7659):E1-E3
pubmed: 28640258
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
Psychopharmacology (Berl). 2013 Jul;228(1):157-66
pubmed: 23455595
Front Neurosci. 2019 Jun 18;13:616
pubmed: 31275104
Arch Gen Psychiatry. 2010 Aug;67(8):793-802
pubmed: 20679587
Am J Psychiatry. 2019 May 1;176(5):401-409
pubmed: 30922101
Hepatology. 2003 Oct;38(4):978-88
pubmed: 14512885
Biol Psychiatry. 2009 Jul 1;66(1):84-90
pubmed: 19358977
Nature. 2011 Jul 06;475(7354):27-30
pubmed: 21734685
Acta Pharmacol Sin. 2011 Jan;32(1):3-11
pubmed: 21131999
Mol Psychiatry. 2011 Nov;16(11):1068-70
pubmed: 21502951
Neuroscience. 2019 Feb 1;398:182-192
pubmed: 30537521
BMC Med. 2018 Jul 11;16(1):103
pubmed: 29991347
Sci Rep. 2020 Jun 18;10(1):9927
pubmed: 32555505
Neuroscience. 2015 Apr 2;290:49-60
pubmed: 25595985
Pharmacol Biochem Behav. 2014 Jan;116:137-41
pubmed: 24316345
Neuropsychopharmacology. 2013 Oct;38(11):2268-77
pubmed: 23680942
Lancet. 2016 Mar 19;387(10024):1227-39
pubmed: 26385066
Drug Metab Dispos. 2013 Feb;41(2):263-9
pubmed: 22837389
PLoS One. 2009;4(3):e4936
pubmed: 19295912
Neuropsychopharmacology. 2017 May;42(6):1210-1219
pubmed: 27604566
Subst Abuse Treat Prev Policy. 2014 Sep 22;9:39
pubmed: 25245125
Brain Imaging Behav. 2014 Mar;8(1):119-27
pubmed: 24158718
Neuroimage. 2011 Feb 14;54(4):2643-51
pubmed: 21073959
Hum Psychopharmacol. 2015 May;30(3):152-63
pubmed: 25847818
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Patient Prefer Adherence. 2012;6:369-88
pubmed: 22654508
Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):297-302
pubmed: 30559184
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):140-4
pubmed: 17884272
Science. 2019 Apr 12;364(6436):
pubmed: 30975859
Drug Metab Dispos. 2001 Jun;29(6):887-90
pubmed: 11353758
Drug Metab Dispos. 2007 Oct;35(10):1935-41
pubmed: 17646279
Anesthesiology. 1997 Apr;86(4):903-17
pubmed: 9105235
Neuron. 2005 Mar 3;45(5):651-60
pubmed: 15748841
Behav Brain Res. 2016 Oct 1;312:305-12
pubmed: 27343934
Biochem Pharmacol. 2012 Jul 1;84(1):93-103
pubmed: 22484313
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
Nat Med. 2014 May;20(5):531-5
pubmed: 24728411
Science. 2010 Aug 20;329(5994):959-64
pubmed: 20724638
Psychol Bull. 2017 Aug;143(8):783-822
pubmed: 28447828
Annu Rev Biochem. 2003;72:609-42
pubmed: 12676795
Front Psychiatry. 2018 Jan 17;8:308
pubmed: 29387021
Biol Psychiatry. 2010 Jan 15;67(2):139-45
pubmed: 19897179
Biol Psychiatry. 2009 Sep 1;66(5):522-6
pubmed: 19545857
Am J Psychiatry. 2000 Sep;157(9):1423-8
pubmed: 10964858
Am J Psychiatry. 2018 Apr 1;175(4):327-335
pubmed: 29202655
J Clin Psychopharmacol. 2005 Aug;25(4):318-24
pubmed: 16012273
Xenobiotica. 2012 Nov;42(11):1076-87
pubmed: 22612619
J Affect Disord. 2014 Feb;155:123-9
pubmed: 24268616
Biol Psychiatry. 2016 Sep 15;80(6):448-456
pubmed: 26957131
Nature. 2021 Feb;590(7845):315-319
pubmed: 33328636
Psychopharmacology (Berl). 2016 Oct;233(21-22):3673-3684
pubmed: 27530989
Basic Clin Pharmacol Toxicol. 2008 Dec;103(6):502-6
pubmed: 19067677
Anesthesiology. 2009 Oct;111(4):892-903
pubmed: 19741495
Neuropharmacology. 2017 Jul 15;121:195-203
pubmed: 28479397
Neurosci Lett. 2015 Jul 23;600:12-6
pubmed: 26033186
J Neurosci. 2007 Dec 12;27(50):13706-18
pubmed: 18077682
Biol Psychiatry. 2017 Sep 1;82(5):e43-e44
pubmed: 28104224
Neuropsychopharmacology. 2013 Dec;38(13):2666-74
pubmed: 23880871
Biol Psychiatry. 2017 Apr 15;81(8):e65-e67
pubmed: 27817845
Psychopharmacology (Berl). 2017 Sep;234(18):2683-2696
pubmed: 28589265
Nature. 2011 Jun 15;475(7354):91-5
pubmed: 21677641
Lancet Psychiatry. 2017 Jan;4(1):9-11
pubmed: 27856394
Prog Neurobiol. 2019 May;176:86-102
pubmed: 30721749
Physiol Behav. 2019 May 1;203:60-69
pubmed: 29055748
Biochem Pharmacol. 1992 Jul 22;44(2):275-83
pubmed: 1642641
Front Neurosci. 2015 Feb 23;9:44
pubmed: 25755630
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Pharmaceuticals (Basel). 2010 Jan 06;3(1):19-41
pubmed: 27713241
J Pharmacol Exp Ther. 2018 Dec;367(3):393-404
pubmed: 30213876
Int J Neuropsychopharmacol. 2018 Oct 1;21(10):932-937
pubmed: 29893929
J Clin Psychiatry. 2010 Dec;71(12):1605-11
pubmed: 20673547
Trends Neurosci. 2010 Feb;33(2):67-75
pubmed: 19963289
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):
pubmed: 25539510
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169
pubmed: 30796190
Behav Brain Res. 2011 Oct 10;224(1):107-11
pubmed: 21669235
Neuropharmacology. 2013 Jul;70:27-34
pubmed: 23337256
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11110-4
pubmed: 7479947
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):450-5
pubmed: 19439250
Int J Environ Res Public Health. 2018 Jul 06;15(7):
pubmed: 29986446
Drug Metab Dispos. 2002 Jul;30(7):853-8
pubmed: 12065445
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209
pubmed: 15364537
Neuropharmacology. 2017 Jan;112(Pt A):198-209
pubmed: 27211253
Mol Pharmacol. 2009 Aug;76(2):215-28
pubmed: 19483103
Brain Struct Funct. 2017 Apr;222(3):1533-1542
pubmed: 27578365
Transl Psychiatry. 2015 Sep 01;5:e632
pubmed: 26327690
Sci Rep. 2016 Feb 18;6:21322
pubmed: 26888470
Psychopharmacology (Berl). 2015 Nov;232(21-22):4231-41
pubmed: 26184011
Brain. 2010 Jul;133(Pt 7):2115-22
pubmed: 20519326
Psychopharmacology (Berl). 2006 Sep;187(4):405-14
pubmed: 16896964
Anesthesiology. 2016 Dec;125(6):1103-1112
pubmed: 27763887
Regul Toxicol Pharmacol. 2016 Jun;77:263-74
pubmed: 26995028
Am J Psychiatry. 2013 Oct;170(10):1134-42
pubmed: 23982301
Biochem Pharmacol. 2018 Jun;152:279-292
pubmed: 29621538
Biol Psychiatry. 2012 Aug 15;72(4):331-8
pubmed: 22516044
Depress Res Treat. 2012;2012:752563
pubmed: 23320155
J Chromatogr A. 2010 Dec 17;1217(51):7942-8
pubmed: 20609441
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Addict Behav. 2013 Jan;38(1):1424-30
pubmed: 23006246
Biol Psychiatry. 2011 Apr 15;69(8):754-61
pubmed: 21292242
Neuro Endocrinol Lett. 2013;34(4):287-93
pubmed: 23803871
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1774-9
pubmed: 21635931
Am J Public Health. 2013 Oct;103 Suppl 1:S93-101
pubmed: 23927517
Harv Rev Psychiatry. 2020 Jan/Feb;28(1):4-13
pubmed: 31913978
J Affect Disord. 2007 Aug;101(1-3):239-44
pubmed: 17173978